CML-IN-1, also known as compound 7 and compound 4, is a potent anticancer agent that demonstrates a strong induced-apoptosis effect in the human chronic myeloid leukemia (CML) cell line K562. It diminishes protein phosphorylation within the PI3K/Akt signaling pathway to exert its effects and suppresses cell proliferation through the inhibition of the MEK/ERK signaling pathway in colorectal cancer [1] [2].

CML-IN-1 (compound 7) exhibited the least cytotoxicity and enhanced bioactivity in cellular assays (K562, IC50: 0.038 µM) [1]. CML-IN-1 (compound 4) significantly inhibited the proliferation of HCT116 cells with IC50 values of 8.04 ± 0.94 µM at 48 hours and 5.52 ± 0.42 µM at 72 hours [2]. Additionally, CML-IN-1 (compound 4) suppressed colony formation, migration, and invasion of HCT116 cells in a dose-dependent manner, induced apoptosis, and caused cell cycle arrest at the G2/M phase [2]. It also inhibited the activation of MEK/ERK signaling pathways in HCT116 cells [2].